Ozone Autohemotherapy (GAE)

Major ozone autohemotherapy (grande autoemotrasfusione, GAE) involves withdrawing a volume of the patient's venous blood, mixing it with a precise concentration of medical-grade ozone, and reinfusing the ozonated blood intravenously. This technique has been studied in the context of immune modulation, circulatory support, and oxidative preconditioning.

Ozone autohemotherapy is one of the longest-established ozone medicine protocols, with clinical use dating back several decades in European integrative medicine. The major autohemotherapy variant (GAE) typically involves drawing 100 to 200 millilitres of venous blood into a sterile, ozone-resistant collection system, exposing it to a calculated dose of medical-grade ozone (an activated form of oxygen), and then returning the treated blood to the patient intravenously. The proposed mechanism centres on oxidative preconditioning: the controlled introduction of ozone-generated reactive oxygen species is thought to upregulate the body's endogenous antioxidant systems, including superoxide dismutase, catalase, and glutathione peroxidase. This hormetic response — where a mild stress stimulus triggers a disproportionately large protective adaptation — is the theoretical basis for the treatment's reported effects on immune function, microcirculation, and tissue oxygenation. Clinical interest in ozone autohemotherapy spans a range of conditions, including chronic fatigue, circulatory insufficiency, immune dysregulation, and post-infectious recovery. In the regenerative medicine context at Image Regenerative Clinic, it is positioned as a systemic therapy aimed at supporting cellular vitality and the body's natural repair capacity. The clinic is led by Professor Carlo Tremolada, whose background in regenerative medicine provides a clinical framework for integrating ozone therapy with other restorative modalities. As with many complementary medical therapies, the evidence base is evolving and individual responses may vary. Patients considering ozone autohemotherapy should discuss their specific health circumstances with the treating physician.